SGIOY - Pfizer set to add nearly $24 billion revenue with COVID-19 pill - Airfinity

Paxlovid, the COVID-19 pill developed by Pfizer (NYSE:PFE), is set to generate $23.6 billion in revenue in 2022 to become one of the fastest-selling treatments of all time, London-based data analytics firm Airfinity Ltd. said Friday, according to Bloomberg. While the consensus sales estimates for Paxlovid stand at $26.9 billion, Pfizer (PFE) projected that the drug would generate $22 billion in revenue early this year. Sales of rival antiviral pills from Merck (MRK)/ Ridgeback Biotherapeutics and Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY) are also expected to climb as case counts rise and previously authorized COVID therapies become ineffective due to the prevalence of new variants. However, Airfinity analyst Arsalan Azad attributed the slow initial rollout of the drugs to factors such as manufacturing constraints, declining hospitalizations, lower COVID testing, and confusion over eligibility.   Pfizer (PFE) antiviral comprising protease inhibitor nirmatrelvir and older antiviral ritonavir was authorized by the U.S. Food and Drug Administration (FDA) last year

For further details see:

Pfizer set to add nearly $24 billion revenue with COVID-19 pill - Airfinity